News

The Manila Times9h
Boehringer ingelheim wins award for kidney disease management for primary care physicians
The Philippine Society of Nephrology (PSN) awarded Boehringer Ingelheim (Philippines) Inc. the prestigious Presidential ...
Contract Pharma12h
The BioMed X Institute, Boehringer Ingelheim Launch Call for Research Proposals
The BioMed X Institute has launched a new global call for research proposals in collaboration with Boehringer Ingelheim.
Fierce Biotech3d
'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts
Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labeled ...
Healio2d
Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks
Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with ...
Boehringer Banks on New Lung Fibrosis Drug Being a Game Changer
Germany’s Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung ...
Clinical Trials Arena on MSN15d
Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophy
The study aims to identify the optimal dose of BI 1584862 and observe its impact on improving GA patients' eyes.
Healio3d
Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks
Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, reduced FVC decline vs. placebo in patients with ...
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for ...
Morningstar29d
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality ...